Cyclic Amide Derivatives Targeting Sigma-2 Receptors for Schizophrenia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sigma-2 receptor-mediated disorders, such as schizophrenia, often have side effects and do not effectively address negative symptoms or cognitive impairments, and there is a need for compounds with selective binding profiles for sigma 2 receptors.
Innovation Solution
Development of cyclic amide derivatives, such as CYR-101, which demonstrate preferential binding to sigma 2 receptors, 5-HT2A receptors, and α1 adrenergic receptors, with minimal affinity for dopaminergic, muscarinic, cholinergic, or histaminergic receptors, for treating these disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional antipsychotic drugs with D2 receptor antagonistic activity are used, then positive symptoms of schizophrenia are treated, but side effects occur and negative symptoms are not effectively addressed
Solution Approach 1:
The patent changes the receptor binding parameters by developing compounds with high affinity for sigma-2 receptors (Ki < 10 nM) while having minimal affinity for other receptors. This parameter change in receptor selectivity allows treatment of schizophrenia symptoms without the side effects associated with non-selective D2 antagonists, achieving both effectiveness and reduced harmful effects.
Solution Approach 2:
The patent segments the receptor binding profile by creating compounds that selectively target specific receptor subtypes (sigma-2 over sigma-1, and over other receptor families). This segmentation of receptor affinity allows the drug to act on the specific pathway (sigma-2) responsible for negative symptoms and cognitive impairments while avoiding off-target effects.
2Adaptability or versatility
If compounds with broad receptor binding activity are used, then multiple symptoms may be addressed, but selectivity for sigma 2 receptors is reduced leading to more side effects
Solution Approach 1:
The patent applies local quality by creating compounds with highly specific binding characteristics tailored to sigma-2 receptors. The molecular structure is designed to fit the sigma-2 binding site precisely, creating a local quality of high affinity (Ki < 10 nM) that is distinct from other receptor types. This localized specificity maintains versatility in treating sigma-2 mediated symptoms while ensuring high selectivity.
3Reliability
If existing sigma ligands are used, then some symptoms are treated, but they do not sufficiently address negative symptoms or cognitive impairments
Solution Approach 1:
The patent changes the pharmacological parameters by identifying and targeting the sigma-2 receptor subtype specifically, which is distinct from sigma-1. This parameter change in receptor subtype selectivity enables the compound to address negative symptoms and cognitive impairments that were not effectively treated by non-selective sigma ligands, while maintaining overall treatment effectiveness.
Data Source
AI summary
Disclosed herein are compositions and methods for treating a sigma-2 receptor-mediated condition or disorder, including treating one or more symptoms of a sigma-2 receptor-mediated condition or disorder.